| Titre : | Dose-escalation in prostate cancer: Results of randomized trials (2022) |
| Auteurs : | M. Kissel ; S.-L. Krhili ; M. Minsat ; R. El Ayachy ; S. Bringer ; L. Lahmi ; J. Porte ; A. Labib ; P. Graff ; G. Crehange |
| Type de document : | Article |
| Dans : | Cancer/Radiothérapie (vol. 26, no. 6-7, Octobre 2022) |
| Article en page(s) : | p. 899-904 |
| Note générale : | https://doi.org/10.1016/j.canrad.2022.07.011 |
| Langues: | Anglais |
| Descripteurs : |
HE Vinci Curiethérapie ; Radiothérapie ; Tumeurs de la prostate |
| Résumé : | In 1998, an editorial from the International Journal of Radiation Oncology – Biology – Physics (IJROBP) on the occasion of the publication of Phase I by Zelefsky et al. on 3D radiotherapy dose escalation asked the question: “will more prove better?”. More than 20 years later, several prospective studies have supported the authors’ conclusions, making dose escalation a new standard in prostate cancer. The data from prospective randomized studies were ultimately disappointing in that they failed to show an overall survival benefit from dose escalation. However, there is a clear and consistent benefit in biochemical recurrence-free survival, which must be weighed on an individual patient basis against the potential additional toxicity of dose escalation. Techniques and concepts have become more and more precise, such as intensity modulated irradiation, simultaneous integrated boost, hypofractionated dose-escalation, pelvic irradiation with involved node boost or focal dose-escalation on gross recurrence after prostatectomy. The objective here was to summarize the prospective data on dose escalation in prostate cancer and in particular on recent advances in the field. In 2022, can we finally say that more has proven better? |
| Disponible en ligne : | Oui |
| En ligne : | https://login.ezproxy.vinci.be/login?url=https://www.sciencedirect.com/science/article/pii/S1278321822001639 |
Bibliothèques HE Vinci
